Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.060 -0.040 (-3.64%)

Streaming Delayed Price Updated: 11:45 AM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

ADCT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 02, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

October 29, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

October 27, 2021

From ADC Therapeutics SA

Via Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

September 29, 2021

From ADC Therapeutics

Via Business Wire

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors

September 27, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 23, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

September 13, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference

September 09, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Medical Leadership Transition

September 03, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty ↗

August 26, 2021

ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics...

Via Benzinga

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

August 26, 2021

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 ↗

August 09, 2021

Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ:

Via Benzinga

ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

ADCT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗

August 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

August 03, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

July 28, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma

June 22, 2021

From ADC Therapeutics SA

Via Business Wire

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

June 18, 2021

From ADC Therapeutics SA

Via Business Wire

Expert Ratings for ADC Therapeutics ↗

June 15, 2021

Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

June 11, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

June 09, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

June 04, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference

May 27, 2021

From ADC Therapeutics SA

Via Business Wire

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

May 26, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

May 19, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield

May 17, 2021

From ADC Therapeutics SA

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.